Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy.

CONCLUSIONS: We are very uncertain whether ALC causes a reduction in pain after 6 to 12 months' treatment in people with DPN, when compared with placebo, as the evidence is sparse and of low certainty. Data on functional and sensory impairment and symptoms are lacking, or of very low certainty. The evidence on adverse events is too uncertain to make any judgements on safety.
PMID: 31201734 [PubMed - as supplied by publisher]

Source: Cochrane Database of Systematic Reviews - June 14, 2019 Category: General Medicine Authors: Rolim LC, da Silva EM, Flumignan RL, Abreu MM, Dib SA Tags: Cochrane Database Syst Rev Source Type: research